We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Muthiah Vaduganathan

Muthiah Vaduganathan MD, MPH

Attending Cardiologist, Division of Cardiovascular Medicine, Brigham and Women’s Hospital; Instructor of Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA). His research focuses on drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 300 peer-reviewed publications. Dr. Vaduganathan serves on the editorial boards of the European Journal of Heart Failure, JACC Heart Failure (Social Media / CME Editor), & JACC (FIT / Early Career Section Editor). He serves as a co-chair on an FDA Think Tank committee on improving future clinical trials in HF. He participates as an investigator and Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.

Disclosures

Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH.